AOP Orphan Pharmaceuticals GmbH

Privately held: no public share price · Austria

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
Type I interferon receptorProtein / enzyme therapeutic
MyelofibrosisPolycythemia VeraEssential Thrombocythemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Ropeginterferon alfa-2b (Besremi)Phase 3Primary Myelofibrosis, Myeloproliferative Neoplasm
Est. primary completion 2027-11-18 · NCT06468033 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Ropeginterferon alfa-2b (Besremi)Phase 3Essential Thrombocythaemia
Est. primary completion 2028-03-15 · NCT06514807 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026ApprovalRopeginterferon alfa-2b (Besremi)FDA Boxed Warning on Besremi (BLA761166)
US, FDA · FDA · Source ↗

Financial reports

No financial reports recorded.